Search for biomarkers in chronic obstructive pulmonary disease: Current status

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 2, 2013, Pages 103-108

  Nicholas, Benjamin L ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

biomarkers; chronic obstructive pulmonary disease; respiratory

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; PROCALCITONIN;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HUMAN; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84873482769     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835ceee5     Document Type: Review

References (40)

1. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: Systematic review and meta-Analysis. Eur Respir J 2006; 28:523-532
2. Poliska S, Csanky E, Szanto A, et al. Chronic obstructive pulmonary diseasespecific gene expression signatures of alveolar macrophages as well as peripheral blood monocytes overlap and correlate with lung function. Respiration 2011; 81:499-510
3. Tilley AE, O'Connor TP, Hackett NR, et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS One 2011; 6:e22798
4. Paige M, Burdick MD, Kim S, et al. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commun 2011; 413:588-593
5. Terracciano R, Preiano M, Palladino GP, et al. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for noninvasive biomarker discovery of chronic inflammatory lung diseases. Proteomics 2011; 11:3402-3414
6. Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-1643
7. Bortner JD Jr, Richie JP Jr, Das A, et al. Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J Proteome Res 2011; 10:1151-1159
8. Tewari AK, Popova-Butler A, El-Mahdy MA, Zweier JL. Identification of differentially expressed proteins in blood plasma of control and cigarette smoke-exposed mice by 2-D DIGE/MS. Proteomics 2011; 11:2051-2062
9. Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD 2012; 9:359-366
10. Miniati M, Monti S, Bottai M, et al. Prognostic value of C-reactive protein in chronic obstructive pulmonary disease. Intern EmergMed 2011; 6:423-430
11. Dahl M, Vestbo J, Zacho J, et al. C reactive protein and chronic obstructive pulmonary disease: A Mendelian randomisation approach. Thorax 2011; 66:197-204
12. Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: Clinical implications. Chest 2008; 134:606-612
13. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-Term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147
14. Nicholas BL, O'Connor CD, Djukanovic R. From proteomics to prescription -The search for COPD biomarkers. COPD 2009; 6:298-303
15. Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res 2011; 12:29
16. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1187-1192
17. Ferhani N, Letuve S, Kozhich A, et al. Expression of high-Mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181:917-927
18. Miniati M, Monti S, Basta G, et al. Soluble receptor for advanced glycation end products in COPD: Relationship with emphysema and chronic cor pulmonale: A case-control study. Respir Res 2011; 12:37
19. Smith DJ, Yerkovich ST, Towers MA, et al. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011; 37:516-522
20. Braber S, Thio M, Blokhuis BR, et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:817-824
21. Bonarius HP, Brandsma CA, Kerstjens HA, et al. Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking history. Thorax 2011; 66:101-107
22. Shiratsuchi N, Asai K, Kanazawa H, et al. Measurement of soluble perforin, a marker of CD8 T lymphocyte activation in epithelial lining fluid. Respir Med 2011; 105:1885-1890
23. Lakhdar R, Denden S, Mouhamed MH, et al. Correlation of EPHX1, GSTP1, GSTM1, and GSTT1 genetic polymorphisms with antioxidative stress markers in chronic obstructive pulmonary disease. Exp Lung Res 2011; 37:195-204
24. Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med 2011; 105 (Suppl. 1):S31-S37
25. Cappello F, Caramori G, Campanella C, et al. Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis. PLoS One 2011; 6:e28200
26. Lindberg CA, Engstrom G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39:839-845
27. Carter RI, Mumford RA, Treonze KM, et al. The fibrinogen cleavage product Aalpha-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 2011; 66:686-691
28. Jouneau S, Khorasani N, DE Souza P, et al. EMMPRIN (CD147) regulation of MMP-9 in bronchial epithelial cells in COPD. Respirology 2011; 16:705-712
29. Asiimwe AC, Brims FJ, Andrews NP, et al. Routine laboratory tests can predict in-hospital mortality in acute exacerbations of COPD. Lung 2011; 189:225-232
30. Zakharkina T, Koczulla AR, Mardanova O, et al. Detection of microorganisms in exhaled breath condensate during acute exacerbations of COPD. Respirology 2011; 16:932-938
31. Lacoma A, Prat C, Andreo F, et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6:157-169
32. Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: A cautionary note. Int J Chron Obstruct Pulmon Dis 2012; 7:127-135
33. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-471
34. Tokman S, Schuetz P, Bent S. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Expert Rev Anti Infect 2011; 9:727-735
35. Almansa R, Sanchez-Garcia M, Herrero A, et al. Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease. J Interferon Cytokine Res 2011; 31:409-413
36. Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011; 12:146
37. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1065-1072
38. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662-671
39. Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012; 83:36-44
40. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of COPD: A randomized placebo controlled trial. Am J Respir Crit Care Med 2012; 186:48-55